Prelude Therapeutics Incorporated (PRLD)
Nasdaq · Healthcare · Biotechnology
$3.77+2.72%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $301M
- 52-week range
- $1.15 – $6.83
- 52-week change
- +154.86%
- EPS (trailing)
- −$0.73
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $12.1M (+73.43%)
- Net income
- −$99.5M
- Operating margin
- −861.4%
- Diluted EPS
- −$1.29
- Free cash flow
- −$56.4M
From the company’s annual report on SEC EDGAR.
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Headquarters: Wilmington, United States · 79 employees · preludetx.com